Cure My Disease

Don't miss your cure!

 Log in / Sign up

Zinc gel may outsmart recurring yeast infections

NCT ID NCT05895162

Disease control Sponsor: FEMPHARMA Kft. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This trial tests whether adding a zinc-containing vaginal gel to the standard yeast infection pill can lower the chance of the infection returning. About 64 women with a current yeast infection will receive either the standard single dose of fluconazole alone or fluconazole followed by the zinc gel for several weeks. Researchers will track how quickly symptoms clear and how many women stay infection-free over about three months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A zinc-containing vaginal gel (JUVIA) used after a single oral dose of fluconazole
What this could lead to
If it works, this could offer a way to cut the common problem of yeast infections coming back after standard treatment.
What could go wrong
The trial is small and early, so the gel may not prove better than fluconazole alone. Some women may find the gel irritating or inconvenient.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

64 people

The number who actually took part.

Started

Jun 2023

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy, nonpregnant female participants aged ≥18 years with a clinical diagnosis of symptomatic acute VVC. * Positive baseline potassium hydroxide (KOH) wet mount from a vaginal smear revealing filamentous hyphae/pseudohyphae or budding yeast cells. * Presence of ≥1 vulvovaginal sign. * Presence of ≥1 vulvovaginal symptom. * Composite Candida severity score of ≥4. Exclusion Criteria: * Abnormal Papanicolaou smear in the preceding 12 months. * Patients who had oral or intravenous antifungal agents within 4 weeks, or used topical vaginal antifungal drugs within 1 week before the study. * Known human immunodeficiency virus infection, * Liver disease or abnormal liver function tests, lactation, pregnancy, and allergy to azole agents or zinc. * Women with non-albicans Candida species will be excluded from the final data analysis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Vaginal yeast infections are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

vulvovaginal candidiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Vaginal yeast infections Vulvovaginal candidiasis

Contacts and locations

Locations

  • Dr. Secret Private Clinic

    Debrecen, HB, 4032, Hungary

More trials for these conditions

Other studies related to the condition(s) this trial covers.